E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Comparison of Levobupivacaine and Ropivacaine for epidural application in obstetric gynaecology
|
|
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
It is the primary aim to show the safety and efficiancy of levobupivacaine when compared to ropivacain as well as patient and user satisfaction in obstetric gynaecology. Under conditions of clinical obstetric gynaecology, the equal use of levobupivacaine and ropivacaine, both approved by the German bord for drug safety, without risk for pregnant women as well as the newborn.
|
|
E.2.2 | Secondary objectives of the trial |
Cardiovascular Parameters (Blood pressure, Heart rate) Patient satisfaction with the medication User satisfaction with the medication Surgeons satisfaction with the medication for caesarean Documentation of Lack of toxic side effects Documentation of analgesic potency Dokumentation of side effects and adverse events Documentation of additionally needed medication Usability of the medication
|
|
E.2.3 | Trial contains a sub-study | Information not present in EudraCT |
E.3 | Principal inclusion criteria |
All pregnant women (ASA I – III) at the date of birth (≥ 36 Week or ≤ 41 SSW), ≥ 18 years, who give written consent (see information and consent) to take part in the trial and do not fullfill one ore more criteria for exclusion as listed below. |
|
E.4 | Principal exclusion criteria |
Refusion of partizipation in the trial Participation in another trial at the same time General contraindications for regional anesthesia Start of th trial between 22.00 Hours and 7.45 hours in the morning Allergic disposition for localanaesthetics of the amide type Eclampsis or preeclampsis HELLP Syndrom History of problems with blood coagulation or medication that inhibits normal blood coagulation. Guidelines of the German Association of Anaesthesiology and intensive Care medicine (DGAI) will be applied (5). Medication with hypnotic effect or sedation up to 12 hours prior epidural analgesia Regular medication with pain reliefing drugs Drug and/or alcohol abuse within the last 12 months Cardiovascular disease of the pregnant woman: Treated or untreated heart insufficiency Arrythmia, treatment with medication needed Valvular defect Septum defect Endo- or myocarditis within the last 12 months Cardiac medication in particular with antiarrhythmics class III or mexiletin myocardial infarcation or angina greater CCS II in medical history Cerebrovascular diseases such as transitoric ischemic attack (TIA) or apoplexia in medical history
Heart attack verified by ECG (new Q waves or ST Elevation), constellation of laboratory parameters (myocardial creatinkinase greater 70 ng/ml or greater 5% of total creatinicinase, Troponin >2) up to 12 hours before epidural catheter.
Treated or untreated epilepsy Prenatal diagnosis of fetal disformities Small for date babies below 1500 gr at date of birth Cognitive impairment of the patient that may cause wrong results or lack of compliance with the trial Chronic disease that might have influence on the results or worsen under the distress of labour and birth Previous participation in the study ASA IV
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
It is the primary aim to show the safety and efficiancy of levobupivacaine when compared to ropivacain as well as patient and user satisfaction in obstetric gynaecology. Under conditions of clinical obstetric gynaecology, the equal use of levobupivacaine and ropivacaine, both approved by the German bord for drug safety, without risk for pregnant women as well as the newborn
Decrease of blood pressure will be different between groups, (levobupivacain vs. ropivacain) assuming that a higher concentration causes a greater decrease: If the difference of decrease in blood pressure is assumend to be 20% for the group of patients giving spontaneous birth the number of patients required will be 72 for each group. Under the assumption that the diffrence will be 25% under ceasarean, the number of patients need will be 43 in each group.
|
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | Yes |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | Yes |
E.6.10 | Pharmacogenetic | Information not present in EudraCT |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.7 | Trial has a data monitoring committee | Information not present in EudraCT |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
The trial end is 24 Hours after the obstretic gynaecology. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | |
E.8.9.1 | In the Member State concerned days | |